Tomoya Miyakawa

USPTO Granted Patents = 15 (Patent Applications = 6)

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 13 (Patent Applications = 15)

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 16(Granted Patents)

Location History:

Minato-ku, JP (2012)
Tokyo, JP (2013 - 2023)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448413 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell (2025-10-21),

2. 11759518 - Medicine for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein (2023-09-19),

3. 11618770 - MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using same (2023-04-04),

4. 11491204 - Composition comprising poly I:C and LAG-3-IGG fusion protein (2022-11-08),

5. 11304997 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell (2022-04-19),

6. 11291718 - Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein (2022-04-05),

7. 10875900 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells (2020-12-29),

8. 10842848 - Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein (2020-11-24),

9. 10590179 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells (2020-03-17),

10. 10537626 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell (2020-01-21),

11. 10526388 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells (2020-01-07),

12. 9353151 - HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptide (2016-05-31),

13. 9045531 - HLA-binding peptide, precursor thereof, and DNA fragment and recombinant vector coding for said HLA-binding peptide (2015-06-02),

14. 8487076 - HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptide (2013-07-16),

15. 8324345 - HLA-binding peptide, precursor thereof, DNA fragment and recombinant vector encoding the same (2012-12-04),

Title: Innovations of Inventor Tomoya Miyakawa

Introduction

Tomoya Miyakawa is a prominent inventor based in Tokyo, Japan, known for his significant contributions to the field of medicine. With a total of 14 patents to his name, Miyakawa's innovative work focuses primarily on cancer treatment and immunology. His research has profound implications for the advancement of therapeutic approaches in oncology.

Latest Patents

Among his latest patents, Miyakawa has developed groundbreaking inventions such as a medicine for treating cancer that employs a Toll-like receptor agonist and a LAG-3 IgG fusion protein. This invention presents a unique pharmaceutical composition that includes a Toll-like receptor agonist, LAG-3 protein, or its variants, along with a MUC1-derived peptide designed to enhance the treatment or prevention of cancer. Additionally, another notable patent outlines an immunity-inducing agent and a method for manufacturing antigen-presenting cells, utilizing peptides comprising specific amino acid sequences, thereby expanding the frontiers of immunotherapy.

Career Highlights

Throughout his career, Tomoya Miyakawa has been associated with several notable companies, including Cytlimic Inc. and NEC Corporation. His work in these organizations has been pivotal in transforming innovative ideas into practical applications, bridging the gap between research and real-world solutions in medical science.

Collaborations

Miyakawa's innovative journey is marked by collaborations with talented professionals in the field. Notable coworkers, including Koji Tamada and Keiko Udaka, have joined him in pioneering research efforts, contributing to the successful advancement of his projects and patents. These collaborations emphasize the importance of teamwork in technological advancements and innovation.

Conclusion

In conclusion, Tomoya Miyakawa stands out as a leading inventor whose work continues to shape the landscape of cancer treatment and immunology. His 14 patents reflect a dedicated commitment to scientific exploration and improving patient outcomes. As the field of medicine progresses, Miyakawa’s contributions will undoubtedly leave a lasting impact on future innovations.

This text is generated by artificial intelligence and may not be accurate.